In vitro postantibiotic effects of tomopenem (CS-023)against Staphylococcus aureus and Pseudomonas aeruginosa

References

1. Bax R. P., Bastain W., Featherstone A., Wilkinson D. M., Hutchison M., Haworth S. J. 1989; The pharmacokineticsof meropenem in volunteers. J Antimicrob Chemother 24 (Suppl. A):311–320
   [Google Scholar]
2. CLSI 2006 Methods for DilutionAntimicrobial Susceptibility Tests for Bacteria that Grow Aerobically ,7th edn, approved standard M7–A7 Wayne, PA: Clinical and LaboratoryStandards Institute;
   [Google Scholar]
3. Craig W. A., Gudmundsson S. 1996; The postantibiotic effect. In Antibiotics in Laboratory Medicine , 4th edn. pp 296–329 Edited by Lorian V. Baltimore, MD: Williams &Wilkins;
   [Google Scholar]
4. Drusano G. L., Standiford H. C. 1985; Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Am J Med 78 (Suppl. 6A):47–53
   [Google Scholar]
5. Gould I. M., Jason A. C., Milne K. 1989; Use of the Malthus microbial growth analyser to study the postantibiotic effect of antibiotics. J Antimicrob Chemother 24:523–531 [CrossRef]
   [Google Scholar]
6. Hanssen A. M., Ericson Solid J. U. 2006; SCC mec in staphylococci: genes on the move. FEMS Immunol Med Microbiol 46:8–20 [CrossRef]
   [Google Scholar]
7. Koga T., Abe T., Inoue H., Takenouchi T., Kitayama A., Yoshida T., Masuda N., Sugihara C., Kakuta M. other authors 2005; In vitro and in vivo antibacterial activity of CS-023 (RO4908463),a novel parenteral carbapenem. Antimicrob Agents Chemother 49:3239–3250 [CrossRef]
   [Google Scholar]
8. Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T. 2008; Potent in vitro activityof tomopenem (CS-023) against methicillin-resistant Staphylococcusaureus and Pseudomonas aeruginosa . Antimicrob AgentsChemother 52:2849–2854
   [Google Scholar]
9. Koga T, Sugihara C, Kakuta M, Masuda N, Namba E, Fukuoka T. 2009; Affinity of tomopenem (CS-023)for penicillin-binding proteins in Staphylococcus aureus , Escherichiacoli, and Pseudomonas aeruginosa . Antimicrob AgentsChemother 53:1238–1241
   [Google Scholar]
10. MacGowan A. P., Bowker K. E., Noel A. R. 2008; Pharmacodynamics of the antibacterial effect and emergenceof resistance to tomopenem, formerly RO4908463/CS-023, in an in vitropharmacokinetic model of Staphylococcus aureus infection. Antimicrob Agents Chemother 52:1401–1406 [CrossRef]
    [Google Scholar]
11. Odenholt I., Isaksson B., Nilsson L., Cars O. 1989; Postantibiotic and bactericidal effect of imipenemagainst Pseudomonas aeruginosa . Eur J Clin Microbiol InfectDis 8:136–141
    [Google Scholar]
12. Odenholt-Tornqvist I., Löwdin E., Cars O. 1991; Pharmacodynamic effects of subinhibitory concentrationsof β -lactam antibiotics in vitro. Antimicrob AgentsChemother 35:1834–1839
    [Google Scholar]
13. Ohya S., Abe T., Ishii C., Kakuta M., Masuda N., Utsui Y., Kuwahara S. 2000; R-115685, a novel parenteralcarbapenem: in vitro antibacterial activity. In Program and Abstractsof the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy , abstract F-1230 Toronto, Canada: American Society for Microbiology;
    [Google Scholar]
14. Quale J., Bratu S., Gupta J., Landman D. 2006; Interplay of efflux system, ampC, and oprD expression incarbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 50:1633–1641 [CrossRef]
    [Google Scholar]
15. Sesoko S., Morita K., Tajima N., Nakashima M. 2006; Safety, tolerability, and pharmacokinetics (PK)of CS-023, a new parenteral carbapenem. in healthy Japanese male volunteers.In Program and Abstracts of the 42nd Interscience Conference on AntimicrobialAgents and Chemotherapy , abstract A-1941 San Francisco: American Societyfor Microbiology;
    [Google Scholar]
16. Shibayama T., Matsushita Y., Hirota T., Ikeda T., Kuwahara S. 2006; Pharmacokinetics of CS-023 (RO4908463),a novel parenteral carbapenem, in healthy male Caucasian volunteers. Antimicrob Agents Chemother 50:4186–4188 [CrossRef]
    [Google Scholar]
17. Shibayama T., Matsushita Y., Kurihara A., Hirota T., Ikeda T. 2007; Prediction of pharmacokinetics ofCS-023 (RO4908463), a novel parenteral carbapenem antibiotic, inhumans using animal data. Xenobiotica 37:91–102 [CrossRef]
    [Google Scholar]
18. Vogelman B. S., Craig W. A. 1985; Postantibiotic effects. J Antimicrob Chemother 15 (Suppl. A):37–46 [CrossRef]
    [Google Scholar]
19. Zhanel G. G., Hoban D. J., Harding G. K. M. 1991; The postantibiotic effect: a review of in vitro andin vivo data. DICP 25:153–163
    [Google Scholar]